The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

The agency will offer earlier meetings with drugmakers as well as solicit more patient feedback on the process.

As CVS pursues a massive cost-cutting plan — and reportedly considers a potential breakup of its businesses — the healthcare behemoth has decided to cut 1% of its workforce.

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch in 2025.

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease, but limited resources.

The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.” ...

IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.